Details

Autor(en) / Beteiligte

• Vandermeulen, Elly
• Lammertyn, Elise
• Verleden, Stijn E.
• Ruttens, David
• Bellon, Hannelore
• Ricciardi, Mario
• Somers, Jana
• Bracke, Ken R.
• Van Den Eynde, Kathleen
• Tousseyn, Thomas
• Brusselle, Guy G.
• Verbeken, Erik K.
• Verschakelen, Johny
• Emonds, Marie‐Paule
• Van Raemdonck, Dirk E.
• Verleden, Geert M.
• Vos, Robin
• Vanaudenaerde, Bart M.

Titel

Immunological diversity in phenotypes of chronic lung allograft dysfunction: a comprehensive immunohistochemical analysis

Ist Teil von

• Transplant international, 2017-02, Vol.30 (2), p.134-143

Ort / Verlag

England: Blackwell Publishing Ltd

Erscheinungsjahr

2017

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Summary Chronic rejection after organ transplantation is defined as a humoral‐ and cell‐mediated immune response directed against the allograft. In lung transplantation, chronic rejection is nowadays clinically defined as a cause of chronic lung allograft dysfunction (CLAD), consisting of different clinical phenotypes including restrictive allograft syndrome (RAS) and bronchiolitis obliterans syndrome (BOS). However, the differential role of humoral and cellular immunity is not investigated up to now. Explant lungs of patients with end‐stage BOS (n = 19) and RAS (n = 18) were assessed for the presence of lymphoid (B and T cells) and myeloid cells (dendritic cells, eosinophils, mast cells, neutrophils, and macrophages) and compared to nontransplant control lung biopsies (n = 21). All myeloid cells, with exception of dendritic cells, were increased in RAS versus control (neutrophils, eosinophils, and mast cells: all P < 0.05, macrophages: P < 0.001). Regarding lymphoid cells, B cells and cytotoxic T cells were increased remarkably in RAS versus control (P < 0.001) and in BOS versus control (P < 0.01). Interestingly, lymphoid follicles were restricted to RAS (P < 0.001 versus control and P < 0.05 versus BOS). Our data suggest an immunological diversity between BOS and RAS, with a more pronounced involvement of the B‐cell response in RAS characterized by a structural organization of lymphoid follicles. This may impact future therapeutic approaches.